Suppr超能文献

经动脉化疗栓塞治疗的肝细胞癌患者肿瘤复发和生存的预测因素

Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.

作者信息

Cerban Razvan, Ester Carmen, Iacob Speranta, Grasu Mugur, Pâslaru Liliana, Dumitru Radu, Lupescu Ioana, Constantin Georgiana, Croitoru Adina, Gheorghe Liana

机构信息

Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Center for Interventional Radiology and Medical Imaging, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest,Romania.

出版信息

J Gastrointestin Liver Dis. 2018 Dec;27(4):409-417. doi: 10.15403/jgld.2014.1121.274.fcr.

Abstract

BACKGROUND AND AIMS

To evaluate the predictive factors for recurrence of the disease and overall survival (OS) after achieving complete response (CR) in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).

METHODS

From January 2013 to December 2017, 168 treatment-naïve patients diagnosed with HCC underwent TACE as a first-line therapy and the gathered data was retrospectively reviewed. We determined the predictive factors for complete response (CR), for recurrence after CR and for survival using the Cox proportional hazard model.

RESULTS

Median follow-up was 27.4 months (range 4-65 months). The mean patient age was 62.2+/-7.9 years. Eighty-three patients had an α-fetoprotein (AFP) level > 20ng/mL. The median maximal diameter of the tumors was 3.5 cm. Sixty-three patients (37.5%) achieved CR after TACE, and recurrence after CR was detected in 37 patients (58.7%). In multivariate analysis, tumor size (</=4.5 cm) and a single tumor were found to be predictive factors for CR, with hazard ratios (HRs) of 2.352 (p=0.022) and 3.964 (p<0.0001), respectively. After achieving CR the median time to recurrence was 12 months (range 6-24 months). Elevated serum AFP > 25 ng/mL and multiple tumors were demonstrated to have a significant relationship with recurrence after CR, with HRs of 1.650 (p=0.05) and 3.932 (p=0.038), respectively. Increased initial serum AFP > 22 ng/mL, tumor size > 4.5 cm, outside Milan criteria, not receiving a liver transplant and presence of portal vein thrombosis (PVT) were correlated with poor survival.

CONCLUSIONS

In patients treated with TACE as an initial therapy, tumor size (≤4.5 cm) and single tumor were predictive factors for CR. Multiple nodules and an elevated serum AFP > 25 ng/mL were predictive factors for recurrence after CR. Outside Milan criteria tumors, elevated AFP levels and the presence of PVT were significantly correlated with decreased survival.

摘要

背景与目的

评估经动脉化疗栓塞术(TACE)治疗的肝细胞癌(HCC)患者达到完全缓解(CR)后疾病复发和总生存期(OS)的预测因素。

方法

2013年1月至2017年12月,168例初治的HCC患者接受TACE作为一线治疗,对收集的数据进行回顾性分析。我们使用Cox比例风险模型确定完全缓解(CR)、CR后复发和生存的预测因素。

结果

中位随访时间为27.4个月(范围4 - 65个月)。患者平均年龄为62.2±7.9岁。83例患者甲胎蛋白(AFP)水平>20ng/mL。肿瘤最大直径中位数为3.5cm。63例患者(37.5%)TACE后达到CR,37例患者(58.7%)检测到CR后复发。多因素分析显示,肿瘤大小(≤4.5cm)和单发病灶是CR的预测因素,风险比(HRs)分别为2.352(p = 0.022)和3.964(p<0.0001)。达到CR后,复发的中位时间为12个月(范围6 - 24个月)。血清AFP>25ng/mL升高和多发病灶与CR后复发显著相关,HRs分别为1.650(p = 0.05)和3.932(p = 0.038)。初始血清AFP>22ng/mL升高、肿瘤大小>4.5cm、超出米兰标准、未接受肝移植和存在门静脉血栓形成(PVT)与生存不良相关。

结论

在以TACE作为初始治疗的患者中,肿瘤大小(≤4.5cm)和单发病灶是CR的预测因素。多个结节和血清AFP>25ng/mL升高是CR后复发的预测因素。超出米兰标准的肿瘤、AFP水平升高和PVT的存在与生存率降低显著相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验